FOLH1 and prostate carcinoma: Recently, Liu et al. reported a novel [18F]AlF-labeled PSMA ligand, [18F]AlF-PSMA-BCH (Figure 8), evaluated through a preclinical study and a pilot clinical study on 11 newly diagnosed prostate cancer patients [101].